162012-70-6

Basic information

• Product Name: 4-CHLORO-7-FLUORO-6-NITRO-QUINAZOLINE
• Synonyms: 4-CHLORO-7-FLUORO-6-NITRO-QUINAZOLINE;4-chloro-6-nitro-7-fluoro-quinazoline;4-CHLORO-7-FLUORO-6-NITRO-QUINAZOLINE###162012-70-6
• CAS NO: 162012-70-6
• Molecular Formula: C₈H₃ClFN₃O₂
• Molecular Weight: 227.58
• Mol File: 162012-70-6.mol
• Article Data: 61

Chemical Properties

• Boiling Point: 395℃
• Flash Point: 193℃
• Appearance: /
• Density: 1.649
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.673
• Storage Temp.: Sealed in dry,Store in freezer, under -20°C
• PKA: 0.53±0.70(Predicted)
• CAS DataBase Reference: 4-CHLORO-7-FLUORO-6-NITRO-QUINAZOLINE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-CHLORO-7-FLUORO-6-NITRO-QUINAZOLINE(162012-70-6)
• EPA Substance Registry System: 4-CHLORO-7-FLUORO-6-NITRO-QUINAZOLINE(162012-70-6)

Safety Data

• Hazard Codes: Xn
• Statements: 22-36
• Safety Statements: 26
• Hazardous Substances Data: 162012-70-6(Hazardous Substances Data)

Usage

Description

4-Chloro-7-fluoro-6-nitro-quinazoline is an organic compound characterized by its quinazoline structure, which features a fused benzene and pyrimidine ring system. 4-Chloro-7-fluoro-6-nitro-quinazoline is notable for its chlorine, fluorine, and nitro functional groups, which contribute to its chemical properties and potential applications in various fields.

Uses

Used in Pharmaceutical Industry:
4-Chloro-7-fluoro-6-nitro-quinazoline is used as an intermediate in the synthesis of Afatinib (A355300), a potent and selective inhibitor of the ErbB family of receptor tyrosine kinases. 4-Chloro-7-fluoro-6-nitro-quinazoline plays a crucial role in the development of Afatinib, which is a valuable drug for treating various types of cancer, including those of the respiratory tract, lungs, gastrointestinal tract, bile duct, and gallbladder. The compound's presence in the synthesis process is essential for the production of an effective therapeutic agent that can help improve the prognosis and quality of life for cancer patients.

InChI:InChI=1/C8H3ClFN3O2/c9-8-4-1-7(13(14)15)5(10)2-6(4)11-3-12-8/h1-3H

Upstream product

• 1194097-41-0 2-amino-4-fluoro-5-nitrobenzoic acid 
• 162012-69-3 7-fluoro-6-nitro-4-hydroxyquinazoline 
• 16499-57-3 7-fluoro-3H-quinazolin-4-one 
• 162012-69-3 7-fluoro-6-nitro-3H-quinazolin-4-one 
• 16499-57-3 7-fluoro-3,4-dihydroquinazolin-4-one 
• 446-32-2 4-fluoroanthranilic acid 

Downstream Products

• 162012-67-1 N-(3-chloro-4-fluorophenyl)-7-fluoro-6-nitroquinazolin-4-amine 
• 1015777-16-8 (7-fluoro-6-nitro-quinazolin-4-yl)-(3-iodo-phenyl)-amine 

Relevant articles and documents

Potential applications of clickable probes in EGFR activity visualization and prediction of EGFR-TKI therapy response for NSCLC patients

The epithelial growth factor receptor (EGFR) is abnormally overexpressed on the cell surface of cancer cells and is strongly associated with cancer cell proliferation, migration, differentiation, apoptosis, and angiogenesis. Tools enabling the visualization of EGFR in a structure-function approach are highly desirable to predict EGFR mutations and guide EGFR tyrosine kinase inhibitor (TKI) treatment making. Here, we describe the design, synthesis, and application of new, potent and selective clickable probes 13 (HX03), 20 (HX04) and 24 (HX05) by introducing an alkyne ligation handle to visualize EGFR activity in living cancer cells and tissue slices. These clickable probes are versatile chemical tools based on the key pharmacophore (4-anilinoquinazoline) of EGFR-TKIs (e.g., canertinib, dacomitinib and afatinib) and are able to irreversibly target the kinase domain of EGFR. Among them, 13 exhibits the highest reactivity towards EGFR kinase, particularly to EGFR kinase with primary mutations. Using activity-based protein profiling strategy, 13 showed high sensitivity and selectivity in labeling of endogenous EGFR in a native cellular context. Moreover, 13 was applied to visualize EGFR mutant activity in tumour tissues from non-small-cell lung cancer (NSCLC) xenograft mouse models, and patients with NSCLC for the prediction of EGFR-TKI sensitivity. These results demonstrate that strategically designed EGFR-TKI-based probes allow discriminating EGFR mutations in human tissues and hold promise as useful diagnostic tools in predicting EGFR-TKI therapy response.

ALKYNYL QUINAZOLINE COMPOUNDS

The present disclosure relates to compounds of Formula (I'): and pharmaceutically acceptable salts and stereoisomers thereof. The present disclosure also relates to methods of preparation these compounds, compositions comprising these compounds, and methods of using them in the prevention or treatment of abnormal cell growth in mammals, especially humans.

Tyrosine kinase inhibitor and pharmaceutical application thereof

The invention relates to a tyrosine kinase inhibitor containing a quinazoline derivative in the fields of tumor treatment medicines and the like, and application of the tyrosine kinase inhibitor in treatment medicines for inhibiting and treating diseases caused by overexpression of tyrosine kinase. The active ingredient of the tyrosine kinase inhibitor is a quinazoline derivative with a structure shown in the following formula: a functional group containing XCH2 (CH2) nC = O is introduced on the basis of a quinazoline structure, and the functional group is easily combined with cysteine sulfydryl through nucleophilic reaction to form a covalent bond so that the activity of tyrosine kinase is irreversibly inhibited.